Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice

Acute myeloid leukemia (AML) remains one of the most lethal, rarely cured cancers, despite decades of active development of AML therapeutics. Currently, the 5-year survival of AML patients is about 30% and for elderly patients, the rate drops to

Saved in:
Bibliographic Details
Published in:EBioMedicine 2019-02, Vol.40, p.231-239
Main Authors: Naganna, N., Opoku-Temeng, Clement, Choi, Eun Yong, Larocque, Elizabeth, Chang, Elizabeth T., Carter-Cooper, Brandon A., Wang, Modi, Torregrosa-Allen, Sandra E., Elzey, Bennett D., Lapidus, Rena G., Sintim, Herman O.
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Anti-leukemic effect
FLT3 kinase inhibitors
FLT3-ITD (D835Y/F691L) inhibition
Research paper
Src kinase inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute myeloid leukemia (AML) remains one of the most lethal, rarely cured cancers, despite decades of active development of AML therapeutics. Currently, the 5-year survival of AML patients is about 30% and for elderly patients, the rate drops to
ISSN:2352-3964
2352-3964
DOI:10.1016/j.ebiom.2019.01.012